2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Chemotherapy, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Research, Fundamental Science, AML, Translational Research, CML, Study Population, Human, Animal Model
PAPER

4964 Multi-omics reveal the heterogeneity and functional remodeling of mesenchymal stromal cells in acute myeloid leukemia

Xi Jia, Zhao Yin2, Qifa Liu, MD3, Xi Xu4
1 Nanfang Hospital, Southern Medical University, guangzhou, China
2 Nanfang Hospital, Southern Medical University, guangzhou, China
3 Nanfang Hospital, Southern Medical University, guangzhou, China
4 Nanfang Hospital, Southern Medical University, guangzhou, China

Background: Bone marrow mesenchymal stromal cells (MSCs) play essential roles in the pathogenesis of acute myeloid leukemia (AML), yet their heterogeneity and spatial organization remain largely uncharacterized. This study aimed to systematically dissect the composition, functional alterations, and clinical relevance of MSC subsets in the AML bone marrow microenvironment at single-cell and spatial resolution.

Methods: We established and optimized an experimental workflow for enzymatic digestion, fluorescence-activated cell sorting, and single-cell RNA sequencing (scRNA-seq) applicable to small bone marrow biopsy specimens. scRNA-seq was performed on 50 AML patients and 15 healthy controls, and 10x Visium spatial transcriptomics was performed on 5 AML samples. Through integrative analysis of single-cell and spatial transcriptomic data, we systematically characterized the subcluster composition, differentiation bias, hematopoietic support capacity, immunomodulatory features, and clinical associations of MSCs and endothelial cells.

Results: Through methodological optimization, the capture efficiency of non-hematopoietic cells was increased from 0.15% to approximately 25%. Single-cell analysis revealed substantial heterogeneity within bone marrow MSCs, identifying six distinct functional subclusters (MSC1-MSC6) along with osteoblasts. Compared with healthy controls, AML patients exhibited a significant increase in the adipogenic-prone MSC3 (adipo-MSC) subcluster, whereas osteogenic (MSC5) and fibroblastic (MSC6) subclusters were markedly reduced. Functional analyses demonstrated that AML-MSCs upregulated immunosuppressive factors (TGFB1, IDO1, ARG1) and immune checkpoint molecules (LAG3, TIGIT), while ANGPTL family-mediated MSC-immune cell communications were globally attenuated. Spatial transcriptomics revealed that the spatial proximity between adipo-MSCs and tumor cells was closely associated with patient chemotherapeutic response. Clinical correlation analyses showed that a higher proportion of MSC3 correlated with favorable treatment outcomes, whereas MSC2 was associated with poor prognosis. Mechanistically, adipo-MSCs directly transferred PABPC1 to AML cells, enhancing cell cycle-related protein translation, thereby accelerating disease progression while unexpectedly increasing chemosensitivity.

Conclusion: This study provides the first comprehensive and spatially resolved multiomic atlas of the human AML bone marrow microenvironment, revealing functional reprogramming of MSC subclusters and their associations with clinical prognosis. These findings offer new theoretical insights and potential therapeutic targets for microenvironment-directed AML treatment strategies.

Xi Jia: No relevant conflicts of interest to declare.